Schubert & Co’s Insmed INSM Stock Holding History

Schubert & Co’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$69	–	746
2023 Q1	$69	Buy	+4	New	+$78	﹤0.01%	1622

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schubert & Co's INSM Position: Q2 2023 in Review

Schubert & Co sold out of Insmed (INSM) in Q2 2023, closing a stake of 4 shares — an estimated $69 sold.

Schubert & Co first reported a position in INSM in Q1 2023 and held it in 1 quarter. The position peaked at $69 in Q1 2023. 223 funds tracked by Wall St. Rank hold INSM as of Q2 2023.

Schubert & Co reported no remaining Insmed position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 4 Insmed shares in Q2 2023, an estimated $69.
Schubert & Co first reported a position in Insmed in Q1 2023 and held it in 1 quarter.
Schubert & Co's Insmed position peaked at $69 in Q1 2023.
223 funds tracked by Wall St. Rank held Insmed as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.